A Study of Oral Upadacitinib (RINVOQ) Tablets to Assess Adverse Events and Change in Disease Symptoms in Korean Participants With Moderate to Severe Active Rheumatoid Arthritis, Atopic Dermatitis, Ankylosing Spondylitis or Psoriatic Arthritis
Post-marketing Surveillance to Evaluate the Safety and Effectiveness of Upadacitinib in Korean Patients
Sponsor: AbbVie
Listed as NCT04541810, this observational or N/A phase trial focuses on Ankylosing Spondylitis (AS) and Atopic Dermatitis (AD) and remains completed. Sponsored by AbbVie, it has been updated 21 times since 2021, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
21 versions recorded-
Feb 2026 — Present [monthly]
Completed
Status: Recruiting → Completed
-
Oct 2025 — Feb 2026 [monthly]
Recruiting
-
Sep 2025 — Oct 2025 [monthly]
Recruiting
-
Jan 2025 — Sep 2025 [monthly]
Recruiting
-
Nov 2024 — Jan 2025 [monthly]
Recruiting
▶ Show 16 earlier versions
-
Sep 2024 — Nov 2024 [monthly]
Recruiting
-
Aug 2024 — Sep 2024 [monthly]
Recruiting
-
Jul 2024 — Aug 2024 [monthly]
Recruiting
-
May 2024 — Jul 2024 [monthly]
Recruiting
-
Jan 2024 — May 2024 [monthly]
Recruiting
-
Dec 2023 — Jan 2024 [monthly]
Recruiting
-
Nov 2023 — Dec 2023 [monthly]
Recruiting
-
Oct 2023 — Nov 2023 [monthly]
Recruiting
-
Aug 2023 — Oct 2023 [monthly]
Recruiting
-
Apr 2023 — Aug 2023 [monthly]
Recruiting
-
Dec 2022 — Apr 2023 [monthly]
Recruiting
-
Mar 2022 — Dec 2022 [monthly]
Recruiting
-
Mar 2021 — Mar 2022 [monthly]
Recruiting
Status: Not Yet Recruiting → Recruiting
-
Feb 2021 — Mar 2021 [monthly]
Not Yet Recruiting
-
Jan 2021 — Feb 2021 [monthly]
Not Yet Recruiting
-
Oct 2020 — Jan 2021 [monthly]
Not Yet Recruiting
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- AbbVie
For direct contact, visit the study record on ClinicalTrials.gov .